Category: Research and Developments

Three anti-VEGF drugs are in clinical use for treatment of wet age-related macular degeneration (wAMD). These are Lucentis (ranibizumab), off-label Avastin (bevacizumab), and Eylea (ranibizumab). The rate of stroke from intravitreal injections of Lucentis was found in the early clinical trials to be 0.2% (1 of 525) in the combined group of patients compared to [Read More]

A report at the Hawaiian Eye & Retina 2019 conference revealed another sustained-delivery drug, GB-102, for treatment of wet age-related macular degeneration (AMD).  Graybug Vision’s ADAGIO study has now provided evidence that GB-102 can continuously inhibit activity of VEGF for several months. The treatment was well-tolerated in the study and found to be free of dose [Read More]

New research published this week in Clinical Epigenetics, has identified two new genes linked to the development of age-related macular degeneration (AMD). Led by Dr. Louise Porter at the University of Liverpool, the team identified genes that may become new targets for treatments. 44 human donor eyes were profiled for  levels of DNA methylation (a [Read More]

Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage [Read More]

Kodiak Sciences Inc. has announced promising results from their Phase 1 clinical trial of KSI-301, a novel anti-VEGF compound for the treatment of age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Currently approved anti-VEGF drugs require several monthly “loading dosages” at the beginning of the treatment regimen. Twelve weeks after a single dose [Read More]